REG - Oxford Biomedica PLC - Licence & Supply Agreement with New Partner

Oxford BioMedicaAnnouncement

07/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220907:nRSG5150Ya&default-theme=true

RNS Number : 5150Y  Oxford Biomedica PLC  07 September 2022

 

 

 

Oxford Biomedica signs Licence & Supply Agreement with new partner for
LentiVector(®) platform for late-stage clinical programme

Oxford, UK - 7 September 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces that it has signed a new Licence and Supply Agreement ("LSA") with
an undisclosed US-based late-stage cell and gene therapy company. The LSA
grants the new partner a non-exclusive licence to utilise Oxford Biomedica's
LentiVector(®) platform for its application in their lead programme, a
cell-based therapy targeting a rare indication, putting into place a five-year
clinical supply arrangement.

Under the terms of the LSA, Oxford Biomedica will receive an undisclosed
upfront payment, as well as additional payments related to the development and
manufacturing of lentiviral vectors for use in clinical trials. The Company
will also receive certain development and regulatory milestone payments and an
undisclosed royalty on the net sales of drug product sold that utilises Oxford
Biomedica's LentiVector(®) platform.

 

 Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica,
commented: "This partnership further demonstrates Oxford Biomedica's world
leadership in the delivery of viral vectors for cell and gene therapies and
the momentum we are building, with this being the fifth new or expanded
customer partnership we have announced this year. We look forward to
continuing to build upon our position as a partner of choice to deliver
life-saving cell and gene therapies to patients."

 

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, VP, Corporate Affairs & Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSUESMEESEFU